ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1045
-0,50%
Bitcoin
66.846,12
2,46%
Brent Oil
83,72
0,62%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Allakos Inc (ALLK)

  7. Allakos Inc (ALLK) Notícias

ALLK

Allakos (ALLK)

Allakos Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALLK
DataHoraFonteTítuloCódigoCompanhia
09/05/202418:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLKAllakos Inc
09/05/202417:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
09/05/202417:02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:ALLKAllakos Inc
14/03/202417:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
06/03/202420:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
05/03/202418:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
26/02/202409:02GlobeNewswire Inc.Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024NASDAQ:ALLKAllakos Inc
16/02/202421:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
14/02/202418:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALLKAllakos Inc
12/02/202409:02GlobeNewswire Inc.Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
02/02/202414:31Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALLKAllakos Inc
26/01/202418:20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALLKAllakos Inc
16/01/202409:02GlobeNewswire Inc.Allakos Announces a Restructuring to Focus on Development of AK006NASDAQ:ALLKAllakos Inc
16/01/202409:00GlobeNewswire Inc.Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary EndpointsNASDAQ:ALLKAllakos Inc
05/01/202418:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALLKAllakos Inc
27/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALLKAllakos Inc
13/11/202319:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLKAllakos Inc
13/11/202318:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
30/08/202317:05GlobeNewswire Inc.Allakos Appoints Neil Graham to its Board of DirectorsNASDAQ:ALLKAllakos Inc
09/08/202317:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
02/08/202317:05GlobeNewswire Inc.Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of DirectorsNASDAQ:ALLKAllakos Inc
12/06/202308:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALLKAllakos Inc
12/06/202308:02GlobeNewswire Inc.Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
05/06/202317:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALLKAllakos Inc
05/06/202308:02GlobeNewswire Inc.Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023NASDAQ:ALLKAllakos Inc
02/06/202317:51Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ALLKAllakos Inc
09/05/202317:14Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALLKAllakos Inc
09/05/202317:02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
20/04/202317:25Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ALLKAllakos Inc
17/04/202318:31Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ALLKAllakos Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALLK

Seu Histórico Recente

BIT
USHY
Lyxor Esg Usd High Yield...
NASDAQ
HSGX
Histogenics
EU
SGBW
Societe Generale SCF SGS...
EU
1861T
1861T
DGFX
VLXUSDT
VLX
LSE
BG48
Barclays 29
USOTC
CSEC
California Science and E... (GM)
DBI
I2UD
DAXsubsector Multi Utili...
NASDAQ
XRGC
Xrg
NASDAQ
KOSS
Koss
ASX
MTSKOP
ASX
KDRN
LSE
0OKR
Hellenic Exchanges Athen...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados